5-Amino-1MQ

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in adipose tissue that is associated with obesity and metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ promotes fat cell energy expenditure and reduces lipid accumulation. It is increasingly used as an adjunct to GLP-1 weight loss protocols for enhanced body composition outcomes.

Category
Weight Loss & Metabolic
Demand
Moderate
Route
Oral capsule, subcutaneous injection
FDA status
Compounding eligibility varies; verify current FDA status before prescribing
Also known as
5-amino-1-methylquinolinium5A1MQ

How 5-Amino-1MQ Works

5-Amino-1MQ selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide using SAM (S-adenosyl methionine) as a methyl donor [1]. NNMT is overexpressed in white adipose tissue of obese individuals, where it reduces intracellular NAD+ and SAM concentrations, impairing cellular energy metabolism [2]. By blocking NNMT, 5-Amino-1MQ restores NAD+ and SAM levels in adipocytes, increasing energy expenditure and promoting a metabolically active phenotype in fat cells [1].

Clinical Evidence

Preclinical research by Neelakantan et al. (2018) demonstrated that selective NNMT inhibition in diet-induced obese mice reduced body weight and white adipose tissue mass without affecting food intake [1]. Kraus et al. (2014) established that NNMT is overexpressed in adipose tissue of obese individuals and that its knockdown increases energy expenditure in adipocytes [2]. In vitro studies confirm that NNMT inhibition increases NAD+ content, activates SIRT1 signaling, and reduces lipid accumulation [3]. Human clinical trial data remains limited, with the evidence base primarily consisting of cell culture and animal models.

Clinical Uses

  • Fat metabolism support and adipocyte energy expenditure
  • Body composition optimization (fat reduction without muscle loss)
  • Adjunct to GLP-1 receptor agonist weight loss programs
  • Metabolic syndrome and insulin resistance support
  • Cholesterol and lipid metabolism improvement

Patient Selection and Screening

Best suited as an adjunct therapy for patients already on GLP-1 or incretin-based weight loss programs who seek enhanced body composition outcomes (fat loss with lean mass preservation) [1]. Also appropriate for patients with metabolic syndrome markers who prefer oral administration. Not recommended as monotherapy for clinically significant obesity [3]. Patients should be counseled that human clinical trial data is limited and prescribing is based on mechanistic rationale and clinical experience.

Dosing and Administration

Oral dosing typically ranges from 50mg to 150mg daily, with most protocols using 100mg daily as standard [1]. Some clinicians dose at 50mg twice daily for sustained levels. Injectable formulations (subcutaneous) are used at lower doses. Treatment duration is commonly 8-12 weeks, often cycled. Can be administered with or without food. Monitor metabolic markers (lipid panel, fasting glucose) to assess response [2]. Dosing should be individualized based on clinical judgment and patient goals.

Route
Oral capsule, subcutaneous injection
Protocol notes
Administered as oral capsule (50-150mg daily) or subcutaneous injection. Often used in combination with GLP-1 agonists, dietary intervention, and exercise programs. Duration of use varies by clinical indication and patient response.

Safety and Monitoring

Potential side effects

  • Mild GI discomfort (nausea, bloating) with oral formulations
  • Headache (uncommon)
  • Injection site irritation (with subcutaneous formulations)
  • Limited long-term safety data; no serious adverse events reported in published literature
  • Potential for interaction with NAD+ precursor supplements (theoretical)

Clinical considerations

  • Relatively new compound with limited long-term human safety data
  • Most evidence supporting NNMT inhibition is preclinical (cell culture and animal models)
  • Not a standalone weight loss solution; best positioned as adjunct to full metabolic programs
  • Monitor lipid panel, metabolic markers, and body composition to assess response
  • Mechanism is distinct from GLP-1 agonists, allowing combination use without overlapping pathways

Practice Economics

5-Amino-1MQ is typically priced at $100-250 per month retail, with wholesale costs from compounding pharmacies in the $30-60 range per course. It functions as a high-margin add-on to existing GLP-1 weight loss programs, increasing per-patient revenue without requiring additional office visits [3]. Practices positioning full metabolic optimization (beyond appetite suppression alone) can use 5-Amino-1MQ to differentiate their programs.

FDA Category Status

Compounding eligibility varies; verify current FDA status before prescribing

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

How does 5-Amino-1MQ work differently from GLP-1 medications?

GLP-1 agonists reduce appetite and slow gastric emptying centrally and peripherally. 5-Amino-1MQ works at the adipocyte level by inhibiting NNMT, an enzyme that when overexpressed allows fat cells to remain metabolically quiescent. By blocking NNMT, fat cells increase energy expenditure and reduce lipid storage. These non-overlapping mechanisms make combination therapy rational.

Can 5-Amino-1MQ be combined with semaglutide or tirzepatide?

Yes. Because the mechanisms are entirely distinct (central appetite suppression vs. peripheral fat cell metabolism), combination use is common in clinical practice. The combination may help preserve lean mass during rapid weight loss and enhance fat-specific metabolic activity. No known pharmacokinetic interactions exist between the compounds.

What is the current evidence base for 5-Amino-1MQ?

The evidence base is primarily preclinical. In vitro and animal studies demonstrate NNMT inhibition reduces fat cell size, increases cellular energy expenditure (NAD+ and SAM levels), and improves metabolic markers. Published human clinical trial data is limited. Physicians should counsel patients that this compound is used based on mechanistic rationale and clinical practice experience rather than large-scale RCTs.

References

  1. Neelakantan et al. - Selective and Membrane-Permeable NNMT Inhibitors for Obesity (Biochemical Pharmacology 2018)
  2. Kraus et al. - NNMT Overexpression in Adipose Tissue and Its Role in Obesity (Nature 2014)
  3. Pissios - NNMT: A Promising Drug Target for Obesity (Trends in Endocrinology and Metabolism 2017)

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs